brl 42810 has been researched along with Herpes Simplex Virus Infection in 67 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Herpes simplex and herpes zoster infections are common and often treated with antiviral drugs including acyclovir, valacyclovir, and famciclovir." | 7.76 | Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. ( Hviid, A; Pasternak, B, 2010) |
| "BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex." | 7.74 | The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. ( Biswas, S; Field, HJ; Jennens, L, 2007) |
| "Two multicenter, open-label, single-arm, two-phase studies evaluated single-dose pharmacokinetics and single- and multiple-dose safety of a pediatric oral famciclovir formulation (prodrug of penciclovir) in children aged 1 to 12 years with suspicion or evidence of herpes simplex virus (HSV) or varicella-zoster virus (VZV) infection." | 5.14 | Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection. ( Abrams, B; Arguedas, A; Bomgaars, L; De León Castrejón, T; Hamed, K; Kaiser, G; Looby, M; Roberts, M; Rodriguez, A; Sáez-Llorens, X; Spigarelli, MG; Yogev, R; Zhou, W, 2009) |
| "A multicenter, open-label study evaluated the single-dose pharmacokinetics and safety of a pediatric oral famciclovir (prodrug of penciclovir) formulation in infants aged 1 to 12 months with suspicion or evidence of herpes simplex virus infection." | 5.14 | Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children. ( Blumer, J; Hamed, K; Kaiser, G; Rodriguez, A; Sallas, W; Sánchez, PJ, 2010) |
| "To compare the efficacy and safety of 7 days' treatment with famciclovir 500 mg twice a day versus acyclovir 400 mg five times a day, for mucocutaneous herpes simplex virus (HSV) infection in HIV-infected individuals." | 5.09 | Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group. ( Aoki, FY; Lavender, EA; Martel, AY; Parsons, JE; Romanowski, B; Saltzman, RL, 2000) |
| " This analysis examined the possible association between use of antiherpetic medications (acyclovir, valacyclovir or famciclovir) during early pregnancy and gastroschisis, a birth defect of the abdominal wall." | 3.79 | Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007. ( Ahrens, KA; Anderka, MT; Canfield, MA; Feldkamp, ML; Mitchell, AA; Werler, MM, 2013) |
| "Herpes simplex and herpes zoster infections are common and often treated with antiviral drugs including acyclovir, valacyclovir, and famciclovir." | 3.76 | Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. ( Hviid, A; Pasternak, B, 2010) |
| "Acute retinal necrosis (ARN) is a distinct ocular viral syndrome traditionally treated with intravenous acyclovir followed by oral acyclovir." | 3.74 | Treatment of acute retinal necrosis syndrome with oral antiviral medications. ( Aizman, A; Elner, SG; Johnson, MW, 2007) |
| "BAY 57-1293 represents a new class of potent inhibitors of herpes simplex virus (HSV) that target the virus helicase primase complex." | 3.74 | The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1. ( Biswas, S; Field, HJ; Jennens, L, 2007) |
| "To explore the possibility of oral antiviral therapy in lieu of intravenous acyclovir for treating acute retinal necrosis (ARN), a necrotizing retinopathy caused by herpes simplex virus type 1 or 2 or by varicella zoster virus." | 3.73 | Primary treatment of acute retinal necrosis with oral antiviral therapy. ( Emerson, GG; Flaxel, CJ; Rosenbaum, JT; Smith, JR; Wilson, DJ, 2006) |
| "For the primary infection of genital herpes, antiviral therapy with acyclovir is the gold standard." | 3.70 | Update on antiviral therapy for genital herpes infection. ( Geers, TA; Isada, CM, 2000) |
| " Thalidomide (Synovir), developed by Celgene, has received limited approval for the treatment of leprosy." | 3.70 | FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration. ( Highleyman, L, 1998) |
| "The probable multifactorial etiology in Meniere's disease requires that further studies be conducted to determine the effects of antiviral medications." | 2.71 | Randomized double-blinded, placebo-controlled clinical trial of famciclovir for reduction of Ménière's disease symptoms. ( Derebery, MJ; Fisher, LM; Iqbal, Z, 2004) |
| "No HSV recurrences were seen in 90% of patients receiving famciclovir at either dose." | 2.69 | Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. ( Alster, TS; Nanni, CA, 1999) |
| "Other viruses, including rubella, chikungunya, and zika, have been linked with distinct forms of the disease." | 2.58 | Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective. ( Bodaghi, B; Garweg, JG; Zandi, S, 2018) |
| "Herpes simplex virus infection is increasingly common in the United States." | 2.41 | Treatment of common cutaneous herpes simplex virus infections. ( Emmert, DH, 2000) |
| "Herpes simplex virus and varicella-zoster virus are common infections and are seen frequently in clinical practice." | 2.40 | Management of herpes simplex and varicella-zoster virus infections. ( Erlich, KS, 1997) |
| "She initially was treated with standard migraine headache medications without symptomatic improvement." | 1.48 | Migraine Headache Treated with Famciclovir and Celecoxib: A Case Report. ( Morimoto, M; Napier, BL; Napier, E, 2018) |
| " Six of 16 patients (37%) receiving long-term oral acyclovir had recurrent HSV, at least one case of which followed a growth spurt that caused the baseline dosage of acyclovir to become subtherapeutic." | 1.38 | Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes. ( Colby, KA; Liu, S; Pavan-Langston, D, 2012) |
| " Prophylactic oral antiviral agents are administered routinely to patients undergoing laser resurfacing to prevent postoperative HSV-1 eruptions; however, dosage and duration of treatment vary in the literature." | 1.32 | Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing. ( Bisaccia, E; Scarborough, D, 2003) |
| " When dosing was reduced to once per day, both compounds were less effective at controlling the infection." | 1.29 | Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model. ( Field, HJ; Sutton, D; Tewari, D; Thackray, AM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (32.84) | 18.2507 |
| 2000's | 32 (47.76) | 29.6817 |
| 2010's | 12 (17.91) | 24.3611 |
| 2020's | 1 (1.49) | 2.80 |
| Authors | Studies |
|---|---|
| Sáez-Llorens, X | 1 |
| Yogev, R | 1 |
| Arguedas, A | 1 |
| Rodriguez, A | 2 |
| Spigarelli, MG | 1 |
| De León Castrejón, T | 1 |
| Bomgaars, L | 1 |
| Roberts, M | 1 |
| Abrams, B | 1 |
| Zhou, W | 1 |
| Looby, M | 1 |
| Kaiser, G | 2 |
| Hamed, K | 2 |
| Blumer, J | 1 |
| Sánchez, PJ | 1 |
| Sallas, W | 1 |
| Gu, Y | 1 |
| Sun, J | 1 |
| Zhang, J | 1 |
| Tsunoda, K | 1 |
| Endo, R | 1 |
| Napier, BL | 1 |
| Morimoto, M | 1 |
| Napier, E | 1 |
| Zandi, S | 1 |
| Bodaghi, B | 1 |
| Garweg, JG | 1 |
| Ahrens, KA | 1 |
| Anderka, MT | 1 |
| Feldkamp, ML | 1 |
| Canfield, MA | 1 |
| Mitchell, AA | 1 |
| Werler, MM | 1 |
| Routt, E | 1 |
| Levitt, J | 1 |
| Gagyor, I | 2 |
| Madhok, VB | 2 |
| Daly, F | 2 |
| Somasundara, D | 2 |
| Sullivan, M | 2 |
| Gammie, F | 2 |
| Sullivan, F | 2 |
| Htwe, TH | 1 |
| Bergman, S | 1 |
| Koirala, J | 1 |
| Elsamra, S | 1 |
| Renzulli, JF | 1 |
| Pasternak, B | 1 |
| Hviid, A | 1 |
| Keating, TM | 1 |
| Kurth, AE | 1 |
| Wald, A | 1 |
| Kahle, EM | 1 |
| Barash, EA | 1 |
| Buskin, SE | 1 |
| Liu, S | 1 |
| Pavan-Langston, D | 1 |
| Colby, KA | 1 |
| Wong, RW | 1 |
| Jumper, JM | 1 |
| McDonald, HR | 1 |
| Johnson, RN | 1 |
| Fu, A | 1 |
| Lujan, BJ | 1 |
| Cunningham, ET | 1 |
| Whitley, RJ | 1 |
| Snoeck, R | 1 |
| Brown, TJ | 1 |
| McCrary, M | 1 |
| Tyring, SK | 1 |
| Roustan, G | 1 |
| Portero, F | 1 |
| Martín, P | 1 |
| Anderson, BJ | 1 |
| Bisaccia, E | 1 |
| Scarborough, D | 1 |
| Abashin, VG | 1 |
| Berlev, IV | 1 |
| Pushkarev, AS | 1 |
| Sharma, DK | 1 |
| Ioannidis, J | 2 |
| Wilkinson, D | 2 |
| Derebery, MJ | 1 |
| Fisher, LM | 1 |
| Iqbal, Z | 1 |
| Whitley, R | 1 |
| Emerson, GG | 1 |
| Smith, JR | 1 |
| Wilson, DJ | 1 |
| Rosenbaum, JT | 1 |
| Flaxel, CJ | 1 |
| Haasz, M | 1 |
| Bonnycastle, M | 1 |
| Dylewski, J | 1 |
| Opatrny, L | 1 |
| Aizman, A | 1 |
| Johnson, MW | 1 |
| Elner, SG | 1 |
| Biswas, S | 1 |
| Jennens, L | 1 |
| Field, HJ | 8 |
| Smith, DE | 1 |
| Gold, J | 1 |
| Garner, HR | 1 |
| Latkany, P | 1 |
| Tewari, D | 1 |
| Sutton, D | 2 |
| Thackray, AM | 7 |
| Ashton, RJ | 1 |
| Abbott, KH | 1 |
| Smith, GM | 1 |
| Easterbrook, P | 1 |
| Wood, MJ | 1 |
| Erlich, KS | 1 |
| Dover, JS | 1 |
| Arndt, KA | 1 |
| Schacker, T | 1 |
| Hu, HL | 1 |
| Koelle, DM | 1 |
| Zeh, J | 1 |
| Saltzman, R | 1 |
| Boon, R | 1 |
| Shaughnessy, M | 1 |
| Barnum, G | 1 |
| Corey, L | 1 |
| Wutzler, P | 1 |
| Angel, S | 1 |
| Boineau-Géniaux, D | 1 |
| Salag, P | 1 |
| Trepsat, F | 1 |
| Chosidow, O | 1 |
| Perrot, JL | 1 |
| Will, F | 1 |
| Grognard, C | 1 |
| Hay, KA | 1 |
| Edris, WA | 1 |
| Gaydos, A | 1 |
| Tenser, RB | 1 |
| Alster, TS | 1 |
| Nanni, CA | 1 |
| LeBlanc, RA | 1 |
| Pesnicak, L | 1 |
| Godleski, M | 1 |
| Straus, SE | 1 |
| Sacks, SL | 1 |
| Wilson, B | 1 |
| Wall, SH | 1 |
| Ramey, SJ | 1 |
| Wall, F | 1 |
| Emmert, DH | 1 |
| Romanowski, B | 1 |
| Aoki, FY | 1 |
| Martel, AY | 1 |
| Lavender, EA | 1 |
| Parsons, JE | 1 |
| Saltzman, RL | 1 |
| Geers, TA | 1 |
| Isada, CM | 1 |
| Manian, FA | 1 |
| Highleyman, L | 1 |
| Prescott, LM | 1 |
| Loutsch, JM | 1 |
| Sainz, B | 1 |
| Marquart, ME | 1 |
| Zheng, X | 1 |
| Kesavan, P | 1 |
| Higaki, S | 1 |
| Hill, JM | 1 |
| Tal-Singer, R | 1 |
| Sohn, S | 1 |
| Bang, D | 1 |
| Lee, ES | 1 |
| Kwon, HJ | 1 |
| Lee, SI | 1 |
| Lee, S | 1 |
| Shaw, MM | 1 |
| Gürr, WK | 1 |
| Watts, PA | 1 |
| Littler, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics and Safety of Famciclovir Oral Pediatric Formulation in Children 1-12 Years of Age With Varicella Zoster Infection[NCT00098046] | Phase 3 | 76 participants (Anticipated) | Interventional | 2005-07-31 | Completed | ||
| A Multicenter, Open-label, Single-arm, Two-step Study to Evaluate the Safety and Single-dose Pharmacokinetics of Famciclovir and Multiple-dose Safety After Administration of Famciclovir Oral Pediatric Formulation to Children 1 to 12 Years of Age With Herp[NCT00098059] | Phase 3 | 74 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Multicenter, Open-label, Single-arm Study to Evaluate the Single-dose Pharmacokinetics, Acceptability and Safety of Famciclovir Oral Pediatric Formulation in Infants 1 Month to Less Than 1 Year of Age With Herpes Simplex Virus Infections[NCT00448227] | Phase 2 | 18 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| An Open Label Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants[NCT00942084] | Phase 1 | 32 participants (Actual) | Interventional | 2011-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
| Intervention | L/h (Mean) |
|---|---|
| 1 to < 2 Years | 20.8 |
| 2 to <6 Years | 25.1 |
| 6 to <=12 Years | 43.7 |
| 13 to <= 18 Years | 68.8 |
PK parameter; penciclovir is the active metabolite of famciclovir (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
| Intervention | hours (Mean) |
|---|---|
| 1 to < 2 Years | 1.09 |
| 2 to <6 Years | 1.36 |
| 6 to <=12 Years | 1.60 |
| 13 to <= 18 Years | 1.86 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
| Intervention | (μg/mL)h (Mean) |
|---|---|
| 1 to < 2 Years | 6.17 |
| 2 to <6 Years | 6.85 |
| 6 to <=12 Years | 8.15 |
| 13 to <= 18 Years | 5.93 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
| Intervention | μg/mL (Mean) |
|---|---|
| 1 to < 2 Years | 2.84 |
| 2 to <6 Years | 2.44 |
| 6 to <=12 Years | 2.82 |
| 13 to <= 18 Years | 1.89 |
PK parameter; penciclovir is the active metabolite of famciclovir. (NCT00098059)
Timeframe: Plasma level measurements: pre-dose, 1, 2, 3, 4 and 5 hours post-dose
| Intervention | hours (Median) |
|---|---|
| 1 to < 2 Years | 1.21 |
| 2 to <6 Years | 1.07 |
| 6 to <=12 Years | 1.00 |
| 13 to < =18 Years | 1.47 |
Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1, after swallowing the dose.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Badly | Neither bad nor good | Well | |
| 1 to < 2 Years | 1 | 1 | 2 |
| 13 to <=18 Years | 2 | 0 | 0 |
| 2 to <6 Years | 4 | 1 | 8 |
| 6 to <13 Years | 0 | 4 | 4 |
Overall acceptability of study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 8 at home: after swallowing last dose
| Intervention | participants (Number) | ||
|---|---|---|---|
| Badly | Neither bad nor good | Well | |
| 1 to < 2 Years | 7 | 3 | 3 |
| 2 to <6 Years | 5 | 3 | 7 |
| 6 to <13 Years | 3 | 3 | 11 |
Overall acceptability of the study medication was determined by caretaker response. (NCT00098059)
Timeframe: Day 1 at clinic: after swallowing first dose
| Intervention | participants (Number) | ||
|---|---|---|---|
| Badly | Neither bad nor good | Well | |
| 1 to < 2 Years | 9 | 2 | 2 |
| 2 to <6 Years | 6 | 1 | 9 |
| 6 to <13 Years | 7 | 2 | 9 |
A patient with multiple adverse events (AEs) within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: 8 hours and 24 hours after study drug administration (Part A)
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| Patients with AEs | Gastrointestinal disorders | Nervous system disorders | General disorders and administration site | Infections and infestations | Skin and subcutaneous tissue disorders | |
| 1 to < 2 Years | 0 | 0 | 0 | 0 | 0 | 0 |
| 13 to <= 18 Years | 2 | 1 | 1 | 1 | 0 | 0 |
| 2 to <6 Years | 2 | 1 | 0 | 0 | 1 | 1 |
| 6 to <=12 Years | 1 | 0 | 1 | 0 | 0 | 0 |
A patient with multiple AEs within the primary system organ class is counted only once in total row. (NCT00098059)
Timeframe: Administered 2 times daily over 7 days
| Intervention | participants (Number) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients with AEs | Gastrointestinal disorders | Nervous system disorders | General disorders and administration site | Respiratory, thoracic and mediastinal disorders | Infections and infestations | Skin and subcutaneous tissue disorders | Vascular disorders | Injury, poisoning and procedural complications | Investigations | Metabolism and nutrition disorders | |
| 1 to < 2 Years | 6 | 4 | 0 | 3 | 1 | 3 | 1 | 0 | 0 | 1 | 1 |
| 2 to <6 Years | 8 | 3 | 2 | 1 | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
| 6 to <13 Years | 12 | 6 | 5 | 1 | 2 | 0 | 0 | 2 | 1 | 0 | 0 |
Measured by AUC(0-6h) - Area under the plasma concentration time curve from time zero up to 6 hours post dose (i.e. the time of the last sample). (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | (μg/mL)•h (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 2.22 |
| Famciclovir: Infants 3 to <6 Months | 3.16 |
| Famciclovir: Infants 6 to 12 Months | 8.77 |
Measured by AUC(0-tlast) - Area under the plasma concentration time curve from time zero to the last quantifiable concentration-timepoint. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | (μg/mL)•h (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 2.09 |
| Famciclovir: Infants 3 to <6 Months | 3.16 |
| Famciclovir: Infants 6 to 12 Months | 8.68 |
Measured by Cmax - The maximum plasma concentration of study medication (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | μg/mL (Mean) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 0.69 |
| Famciclovir: Infants 3 to <6 Months | 0.74 |
| Famciclovir: Infants 6 to 12 Months | 3.24 |
Measured by Tmax - The time after administration of a drug when the maximum plasma concentration is reached. (NCT00448227)
Timeframe: Plasma samples were collected at 0.5, 1, 4 and 6 hours after dosing.
| Intervention | hours (Median) |
|---|---|
| Famciclovir: Infants 1 to <3 Months | 1.00 |
| Famciclovir: Infants 3 to <6 Months | 4 |
| Famciclovir: Infants 6 to 12 Months | 1.02 |
"Assessed by the study personnel using a 5-point scale after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very badly / unacceptable | Badly but accepted | Neither good nor bad | Well accepted | Very well accepted | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 2 | 4 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 2 | 0 | 3 |
| Famciclovir: Infants 6 to 12 Months | 0 | 1 | 2 | 1 | 1 |
| Total | 1 | 1 | 4 | 3 | 8 |
"Assessed by the caregiver using a 5-point scale immediately after dosing:~Very badly accepted/unacceptable: infant showed great displeasure, compromising use of formulation~Badly but accepted: infant showed displeasure with dosing but could be coaxed to take complete dose~Neither good nor bad: infant showed no apparent displeasure and with little effort was coaxed to take complete dose~Well accepted: infant appeared to enjoy the formulation and with little coaxing ingested most of dose~Very well accepted: infant appeared eager and ingested most of dose without special coaxing" (NCT00448227)
Timeframe: Immediately after dosing
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Very badly / unacceptable | Badly but accepted | Neither good nor bad | Well accepted | Very well accepted | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 2 | 4 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 2 | 0 | 3 |
| Famciclovir: Infants 6 to 12 Months | 0 | 1 | 1 | 2 | 1 |
| Total | 1 | 1 | 3 | 4 | 8 |
"Tolerability was assessed by the study personnel 30 minutes after dosing using the following scale:~Significant emesis occurred,~Infant spit out most of the dose ingesting less than half of what was administered,~Infant spit out some of the dose, but ingested at least 50% of what was administered,~Infant was able to ingest and retain the dose administered" (NCT00448227)
Timeframe: 30 minutes after dosing
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Significant emesis occurred | Spit out most of the dose, ingested less than half | Spit out some of the dose, ingested at least 50% | Able to ingest and retain dose | |
| Famciclovir: Infants 1 to <3 Months | 1 | 0 | 0 | 7 |
| Famciclovir: Infants 3 to <6 Months | 0 | 0 | 0 | 5 |
| Famciclovir: Infants 6 to 12 Months | 0 | 0 | 0 | 5 |
| Total | 1 | 0 | 0 | 17 |
"Timeframe:~Version 1:0-5 min,2-4 hrs,6-8 hrs post doses 1 and 5-15; prior to doses 5-15 Version 2:0-15 min post doses 1 and 5-15; within 30 min prior to doses 2 and 5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose" (NCT00942084)
Timeframe: V1:0-5 min,2-4 hrs,6-8 hrs post Doses 1&5-15;prior to doses 5-15; V2:0-15 min post doses 1&5-15; within 30 min prior to doses 2&5-15; 2-3 hrs post doses 5-15; 15-18 hrs post last dose
| Intervention | L/h/kg (Median) |
|---|---|
| Acyclovir Study Design | 0.278 |
(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring
| Intervention | h (Median) |
|---|---|
| Acyclovir Study Design | 7.07 |
(NCT00942084)
Timeframe: up to 3 dasy of study drug administration and 10 days of safety monitoring
| Intervention | mg/L (Median) |
|---|---|
| Acyclovir Study Design | 11.1 |
(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring
| Intervention | mg/L (Median) |
|---|---|
| Acyclovir Study Design | 4.15 |
(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring
| Intervention | mg/L (Median) |
|---|---|
| Acyclovir Study Design | 6.33 |
(NCT00942084)
Timeframe: up to 3 days of study drug administration and 10 days of safety monitoring
| Intervention | L/kg (Median) |
|---|---|
| Acyclovir Study Design | 3.34 |
16 reviews available for brl 42810 and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
Review for Disease of the Year: Treatment of Viral Anterior Uveitis: A Perspective.
Topics: Acyclovir; Antiviral Agents; Bromodeoxyuridine; Chikungunya Fever; Cytomegalovirus Infections; Eye I | 2018 |
Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
Topics: 2-Aminopurine; Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Bell Palsy; Drug Therapy, Comb | 2015 |
WITHDRAWN: Antiviral treatment for Bell's palsy (idiopathic facial paralysis).
Topics: 2-Aminopurine; Acyclovir; Anti-Inflammatory Agents; Antiviral Agents; Bell Palsy; Drug Therapy, Comb | 2015 |
Emerging concepts in the management of acute retinal necrosis.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cytomegalovirus Retinitis; Eye Infections, Viral; Famcic | 2013 |
Herpes simplex virus infection.
Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Acyclovir; Administration, Oral; Adult; Antiviral | 2002 |
[Perspectives for the treatment and prevention of herpes simplex infections].
Topics: 2-Aminopurine; Acyclovir; Aminoquinolines; Antiviral Agents; Cidofovir; Cytosine; Drug Therapy, Comb | 2002 |
Antiviral agents: Non-antiretroviral [correction of Nonantiviral] drugs.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Cytomegalovirus Infections; Famciclovir; Fos | 2002 |
[Prophylaxis and treatment of herpes in women].
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Female; Herpes Genitalis; Herpes Simplex; H | 2003 |
HIV: prevention of opportunistic infections.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Infective Agents; Antifungal A | 2003 |
HIV: prevention of opportunistic infections.
Topics: 2-Aminopurine; Acyclovir; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-HIV Age | 2005 |
New approaches to the therapy of HSV infections.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Herpes Simplex; Humans; Patient Compliance; Patient Sa | 2006 |
Successors to acyclovir.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Arabinofuranosyluracil; Chickenpox; Drug Resistance, Mic | 1994 |
Management of herpes simplex and varicella-zoster virus infections.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Chickenpox; Child; Famciclovir; Female; Herpes Si | 1997 |
Antiviral therapy of herpes simplex and varicella-zoster virus infections.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Arabinofuranosyluracil; Bromodeoxy | 1997 |
Famciclovir/penciclovir.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Guanine; Herpes Genitalis; Herpes Labialis; | 1999 |
Treatment of common cutaneous herpes simplex virus infections.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chronic Disease; Diagnosis, Differential; Drug Costs; Fa | 2000 |
7 trials available for brl 42810 and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Pharmacokinetics and safety of famciclovir in children with herpes simplex or varicella-zoster virus infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chickenpox; Child; Child, Preschool; Drug Administration | 2009 |
Single-dose pharmacokinetics of famciclovir in infants and population pharmacokinetic analysis in infants and children.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Body Weight; Capsules; Child; Chil | 2010 |
Randomized double-blinded, placebo-controlled clinical trial of famciclovir for reduction of Ménière's disease symptoms.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Dizziness; Double-Blind Method; Famciclovir; Female; Hearing | 2004 |
Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial.
Topics: 2-Aminopurine; Adult; Aged; AIDS-Related Opportunistic Infections; Antibodies, Viral; Antiviral Agen | 1998 |
Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing.
Topics: 2-Aminopurine; Adult; Aged; Antiviral Agents; Facial Dermatoses; Famciclovir; Female; Herpes Simplex | 1999 |
Efficacy and safety of famciclovir for treating mucocutaneous herpes simplex infection in HIV-infected individuals. Collaborative Famciclovir HIV Study Group.
Topics: 2-Aminopurine; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Double-Bli | 2000 |
Famvir effective in suppressing recurrent genital herpes.
Topics: 2-Aminopurine; Antiviral Agents; Double-Blind Method; Famciclovir; Female; Herpes Simplex; Humans; M | 1998 |
44 other studies available for brl 42810 and Herpes Simplex Virus Infection
| Article | Year |
|---|---|
HSV-associated erythema multiforme in a patient after hematopoietic stem cell transplantation.
Topics: Biopsy, Needle; Erythema Multiforme; Famciclovir; Follow-Up Studies; Graft vs Host Disease; Hematopo | 2019 |
Intranasal pain in a patient with Behçet's disease.
Topics: Antiviral Agents; Behcet Syndrome; Blister; Endoscopy; Famciclovir; Female; Glucocorticoids; Herpes | 2020 |
Migraine Headache Treated with Famciclovir and Celecoxib: A Case Report.
Topics: 2-Aminopurine; Antiviral Agents; Celecoxib; Cyclooxygenase 2 Inhibitors; Famciclovir; Female; Herpes | 2018 |
Antiherpetic medication use and the risk of gastroschisis: findings from the National Birth Defects Prevention Study, 1997-2007.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Adult; Antiviral Agents; Case-Control Studies; Famciclovir; Fe | 2013 |
Famciclovir for recurrent herpes-associated erythema multiforme: a series of three cases.
Topics: 2-Aminopurine; Administration, Oral; Adult; Aged; Antiviral Agents; Drug Administration Schedule; Dr | 2014 |
Famciclovir substitution for patients with acyclovir-associated renal toxicity.
Topics: 2-Aminopurine; Acyclovir; Aged; Aged, 80 and over; Antiviral Agents; Famciclovir; Female; Herpes Sim | 2008 |
Acute herpetic infections resulting in acute urinary retention in young women.
Topics: 2-Aminopurine; Acute Disease; Adult; Antiviral Agents; Famciclovir; Female; Herpes Simplex; Herpes Z | 2009 |
Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.
Topics: 2-Aminopurine; Abnormalities, Drug-Induced; Acyclovir; Adolescent; Adult; Antiviral Agents; Cohort S | 2010 |
Clinical burden of herpes simplex virus disease in people with human immunodeficiency virus.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Comorbidity; Famciclovir; Female; Herpes Simplex; | 2012 |
Pediatric herpes simplex of the anterior segment: characteristics, treatment, and outcomes.
Topics: 2-Aminopurine; Acyclovir; Administration, Topical; Adolescent; Age of Onset; Anterior Eye Segment; A | 2012 |
[Acute vesicular eruption over the trunk].
Topics: 2-Aminopurine; Adult; Anti-Bacterial Agents; Cefadroxil; Darier Disease; Famciclovir; Giant Cells; H | 2002 |
The epidemiology and clinical analysis of several outbreaks of herpes gladiatorum.
Topics: 2-Aminopurine; Acyclovir; Adolescent; Antiviral Agents; Disease Outbreaks; Famciclovir; Herpes Simpl | 2003 |
Herpes simplex virus prophylaxis with famciclovir in patients undergoing aesthetic facial CO2 laser resurfacing.
Topics: 2-Aminopurine; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antiviral Agents; Carbon Dioxide; Ceph | 2003 |
Herpes simplex infection of portal wound following arthroscopy of knee joint.
Topics: 2-Aminopurine; Antiviral Agents; Arthroscopy; Famciclovir; Female; Herpes Simplex; Humans; Knee Join | 2004 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Drug Resistance, Viral; Famc | 2005 |
Primary treatment of acute retinal necrosis with oral antiviral therapy.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Adult; Aged; Antiviral Agents; Cytomegalovirus Retin | 2006 |
Beseiged.
Topics: 2-Aminopurine; Adult; Antiviral Agents; Biopsy; Blister; Diagnosis, Differential; Famciclovir; Femal | 2006 |
Treatment of acute retinal necrosis syndrome with oral antiviral medications.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antivira | 2007 |
The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB/c mice infected with herpes simplex virus type 1.
Topics: 2-Aminopurine; Administration, Oral; Animals; Antiviral Agents; Brain Stem; Disease Models, Animal; | 2007 |
Famciclovir or valaciclovir in the management of herpes simplex and varicella zoster infections: an attitudinal survey of clinician perceptions of differential activity.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Attitude of Health Personnel; Australia; Famciclo | 2007 |
Oral drugs for viral retinitis.
Topics: 2-Aminopurine; Acyclovir; Administration, Oral; Antiviral Agents; Eye Infections, Viral; Famciclovir | 2007 |
Comparison of efficacies of famciclovir and valaciclovir against herpes simplex virus type 1 in a murine immunosuppression model.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Cyclosporine; Famciclovir; Female; Fluorescent | 1995 |
Antiviral activity of famciclovir and acyclovir in mice infected intraperitoneally with herpes simplex virus type 1 SC16.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Famciclovir; Herpes Simplex; Herpesvirus 1, Hum | 1994 |
Differential effects of famciclovir and valaciclovir on the pathogenesis of herpes simplex virus in a murine infection model including reactivation from latency.
Topics: 2-Aminopurine; Acute Disease; Acyclovir; Animals; Antiviral Agents; Brain Stem; Disease Models, Anim | 1996 |
Dermatology.
Topics: 2-Aminopurine; Acyclovir; Antifungal Agents; Antiviral Agents; Dermatologic Agents; Dermatology; Der | 1997 |
Famciclovir and valaciclovir differ in the prevention of herpes simplex virus type 1 latency in mice: a quantitative study.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Body Weight; Brain; Cell Culture Techniques; De | 1998 |
[Prevention of facial herpetic infections after chemical peel and dermabrasion: new treatment strategies in the prophylaxis of patients undergoing procedures of the perioral area].
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Chemexfoliation; Chemoprevention; Dermabrasion; Dermatit | 1998 |
Herpes simplex virus latency after direct ganglion virus inoculation.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Cell Survival; Chlorocebus aethiops; Famciclovi | 1998 |
The comparative effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Brain; Chlorocebus aethiops; Eye; Famciclovir; | 1999 |
Famciclovir as antiviral prophylaxis in laser resurfacing procedures.
Topics: 2-Aminopurine; Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Case-Control Studies; D | 1999 |
Effects of famciclovir and valacyclovir on herpes simplex virus type 1 infection, latency, and reactivation in mice: how dissimilar are study results?
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Disease Models, Animal; Famciclovir; Herpes Sim | 2000 |
Further evidence from a murine infection model that famciclovir interferes with the establishment of HSV-1 latent infections.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Famciclovir; Female; Ganglia, Spinal; Herpes Simplex; Herp | 2000 |
Update on antiviral therapy for genital herpes infection.
Topics: 2-Aminopurine; Acyclovir; Antiviral Agents; Famciclovir; Female; Herpes Genitalis; Herpes Simplex; H | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Aged; Amantadine; Animals; Anti-HIV Agents; Antiviral Agents; | 1999 |
The effects of antiviral therapy on the distribution of herpes simplex virus type 1 to ganglionic neurons and its consequences during, immediately following and several months after treatment.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; beta-Galactosidase; Famciclovir; Ganglia; Genes | 2000 |
Potential role of famciclovir for prevention of herpetic whitlow in the health care setting.
Topics: 2-Aminopurine; Administration, Oral; Antibodies, Viral; Antiviral Agents; Famciclovir; Fingers; Heal | 2000 |
Famciclovir safe and effective for herpes.
Topics: 2-Aminopurine; Antiviral Agents; Famciclovir; Herpes Simplex; Humans; Prodrugs | 1997 |
Herpes study and resources.
Topics: 2-Aminopurine; Acyclovir; Adult; Antiviral Agents; Biopolymers; Catechin; Clinical Trials as Topic; | 1997 |
FDA approves fomivirsen, famciclovir, and Thalidomide. Food and Drug Administration.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Cytomegalovirus Retinitis; D | 1998 |
Valuable clinical tips from recent medical meetings.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Congresses as Topic; Famcicl | 1999 |
Antiviral drug reduces shedding of herpes virus.
Topics: 2-Aminopurine; AIDS-Related Opportunistic Infections; Antiviral Agents; Clinical Trials as Topic; Fa | 1998 |
Effect of famciclovir on herpes simplex virus type 1 corneal disease and establishment of latency in rabbits.
Topics: 2-Aminopurine; Acute Disease; Administration, Oral; Administration, Topical; Animals; Antiviral Agen | 2001 |
Experimental studies on the antiviral agent famciclovir in Behçet's disease symptoms in ICR mice.
Topics: 2-Aminopurine; Animals; Antiviral Agents; Behcet Syndrome; Disease Models, Animal; Famciclovir; Herp | 2001 |
Temporal pattern of herpes simplex virus type 1 infection and cell death in the mouse brain stem: influence of guanosine nucleoside analogues.
Topics: 2-Aminopurine; Acyclovir; Animals; Antiviral Agents; Apoptosis; Brain Stem; Disease Models, Animal; | 2002 |